TICKERNERD
Menu
RARERAREHealthcare · Biotechnology

RARE Stock Forecast: Ultragenyx Pharmaceutical, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$17
+3.25% on the day

The 21 Wall Street analysts covering Ultragenyx Pharmaceutical, Inc. hold a median 12-month price target of $24 — +39.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 3 Nov 2026 — in the upper half.

Market cap
$1.6B
Ticker Nerd rank
51/ 100
Median analyst target
$24
Analysts covering
21
Revenue$214.0M+28.5% y/y
Operating income−$75.0M
Net income−$92.0M
Free cash flow−$98.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.2%
1M
+12.8%
YTD
−25.3%
1Y
−47.1%
From 52W high
−53.0%
From 52W low
+33.3%
$13
$37
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RARE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ultragenyx Pharmaceutical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Nov 2026
51/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
89
Value
83
Revisions
61
Accruals
58
Quality
57
Volatility
47
Size
38
Momentum
16
Issuance
12

Growth (89): Sales and profits are climbing, and climbing faster than before.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

RARE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RARE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30$35$40$45Jan 26Apr 26Jul 26Oct 26RAREHigh $39Median $24Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says21 analysts
10 Buy11 Hold0 Sell
Low $16Median $24High $39

The green dot is the last close — the median target sits +39.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
15 Oct 2026UBSInitiatesNeutral$16
21 Sept 2026BarclaysMaintainsOverweight—
21 Sept 2026BarclaysMaintainsOverweight$32 → $35
21 Sept 2026Evercore ISI GroupMaintainsIn-Line$16 → $18
21 Sept 2026Evercore ISI GroupMaintainsIn-Line—
18 Sept 2026Canaccord GenuityMaintainsBuy—
18 Sept 2026Canaccord GenuityMaintainsBuy$37 → $39
18 Sept 2026Cantor FitzgeraldMaintainsOverweight$33 → $39
18 Sept 2026Cantor FitzgeraldMaintainsOverweight—
18 Sept 2026CitigroupMaintainsBuy—
18 Sept 2026CitigroupMaintainsBuy$31 → $32
18 Sept 2026Morgan StanleyMaintainsEqual-Weight$18 → $20
18 Sept 2026Morgan StanleyMaintainsEqual-Weight—
17 Sept 2026CitigroupMaintainsBuy—
17 Sept 2026CitigroupMaintainsBuy$28 → $31
4 Sept 2026BarclaysMaintainsOverweight—
4 Sept 2026BarclaysMaintainsOverweight$43 → $32
4 Sept 2026Goldman SachsMaintainsNeutral—
4 Sept 2026Goldman SachsMaintainsNeutral$28 → $19
3 Sept 2026BairdDowngradeNeutral$40 → $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

RARE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

RARE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Ultragenyx Pharmaceutical, Inc. returned −47.1% against +12.9% for the S&P 500, dividends included.

RARE vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26RARES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RARE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Ultragenyx Pharmaceutical, Inc. (RARE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.8×

Cheaper than 88% of US stocks

Price / sales
2.2×

Cheaper than 48% of US stocks

Price / book
−5.9×

Cheaper than 97% of US stocks

EV / EBITDA
−5.4×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
28.1%

Higher than 77% of US stocks

Earnings growth (YoY)
28.5%

Higher than 66% of US stocks

Gross margin
84.1%

Higher than 93% of US stocks

Operating margin
−35.0%

Higher than 19% of US stocks

Net margin
−81.7%

Higher than 7% of US stocks

Returns & dividend
Return on equity
787.7%

Higher than 99% of US stocks

Return on assets
−24.2%

Higher than 17% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ultragenyx Pharmaceutical, Inc. (RARE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ultragenyx Pharmaceutical, Inc. has a market value of $1.6B and an enterprise value of $2.5B.

  • Revenue in the twelve months to 30 June 2026: $717.2M. The latest quarter grew 28.1% year on year.

  • Net income over the same four quarters: −$586.0M, a −81.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−5.84.

  • Free cash flow in the twelve months to 30 June 2026: −$494.0M.

  • Shares outstanding: 98.6M.

  • Trailing P/E: −2.8×; forward P/E: 72.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Ultragenyx Pharmaceutical, Inc. employs 1,371 people — $523K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 3 Nov 2026

Data provided by Twelve Data

Peers

RARE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RAREUltragenyx Pharmaceutical, Inc.$1.6B51
NUVBNuvation Bio, Inc.$1.7B52
QUREuniQure NV$1.6B40
NTLAIntellia Therapeutics, Inc.$1.7B60
URGNUroGen Pharma Ltd.$1.7B65
NVAXNovavax, Inc.$1.6B61
STOKStoke Therapeutics, Inc.$1.7B19

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ultragenyx Pharmaceutical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RARE news & analysis

Ultragenyx: Still Lacking Appeal Despite 'Commercial-First' Pivot

Seeking Alpha · 4 Nov 2026negative

Ultragenyx remains a cautious “Hold,” with the article saying profitability targets rely on deep R&D cuts rather than strong revenue growth. Q3 revenue rose 8% year over year to $173 million, while revenue remained concentrated in CRYSVITA and new launches contributed minimally amid pipeline setbacks and terminated programs.

Why it matters — The commercial-first pivot and limited revenue diversification may matter to RARE watchers assessing the company’s growth and profitability profile.

Ultragenyx Pushes Toward Profitability in 2027, Led by Pruned Pipeline, Layoffs

Benzinga · 4 Nov 2026negative

Ultragenyx shares traded lower Wednesday after the company initiated substantial expense reductions, aiming to align expenses with revenue and achieve profitability by 2027.

Why it matters — The cost reductions and 2027 profitability goal are relevant to RARE watchers assessing the company’s financial plans.

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2026 Earnings Call Transcript

Seeking Alpha · 4 Nov 2026neutral

Ultragenyx Pharmaceutical held its Q3 2026 earnings call on November 3, 2026, with company executives and analysts participating. The excerpt provides the call details but no discussion of results or business developments.

Why it matters — The excerpt confirms the timing and participants of the earnings call, but does not provide substantive information about the company’s quarter.

What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call

MarketBeat · 4 Nov 2026negative

Ultragenyx said its third quarter included two U.S. gene therapy approvals, a failed late-stage Angelman syndrome study, termination of its Wilson disease program, and restructuring actions intended to support GAAP profitability in 2027.

Why it matters — The update combines regulatory progress with clinical and program setbacks and outlines restructuring tied to the company’s profitability goal.

Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates

Zacks Investment Research · 3 Nov 2026negative

Ultragenyx reported a Q3 loss of $1.16 per share, slightly wider than the Zacks Consensus Estimate of $1.15 per share. The loss was narrower than the $1.81 per share loss reported a year earlier.

Why it matters — RARE watchers may note the quarterly loss exceeded the consensus estimate, while improving year over year.

FAQ

Frequently asked questions about RARE stock

What is the RARE stock price forecast for 2026-2027?

The 21 Wall Street analysts covering Ultragenyx Pharmaceutical, Inc. have a median 12-month price target of $24, with estimates ranging from $16 to $39. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RARE stock a buy right now?

Of the 21 analysts covering Ultragenyx Pharmaceutical, Inc., 10 rate it a Buy, 11 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ultragenyx Pharmaceutical, Inc. 51 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RARE?

As at 3 Nov 2026, Ultragenyx Pharmaceutical, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (89 of 100).

Will RARE stock go up?

No one can know that. What the data says: the median 12-month target from 21 analysts implies +39.8% from the last close, and Ticker Nerd's factor model ranks Ultragenyx Pharmaceutical, Inc. 51 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RARE stock forecast for 2030?

No analyst covering Ultragenyx Pharmaceutical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RARE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $39 over the next 12 months.

How has RARE stock performed over the past year?

Ultragenyx Pharmaceutical, Inc. returned -47.1% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ultragenyx Pharmaceutical, Inc. do?

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing therapies for serious rare and ultra-rare genetic diseases.

What is the latest news on RARE?

The most recent item we track (Seeking Alpha, 4 Nov 2026): "Ultragenyx: Still Lacking Appeal Despite 'Commercial-First' Pivot". Ultragenyx remains a cautious “Hold,” with the article saying profitability targets rely on deep R&D cuts rather than strong revenue growth. Q3 revenue rose 8% year over year to $173 million, while revenue remained concentrated in CRYSVITA and new launches contributed minimally amid pipeline setbacks and terminated programs.

Company

About Ultragenyx Pharmaceutical, Inc.

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing therapies for serious rare and ultra-rare genetic diseases. Its current portfolio includes Crysvita, an antibody treatment for X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for mucopolysaccharidosis VII; Dojolvi, a nutritional therapy for long-chain fatty acid oxidation disorders; and Evkeeza, a treatment for homozygous familial hypercholesterolemia. The company also develops medicines across biologics, small molecules, gene therapy, and nucleic acid technologies, addressing conditions with limited treatment options. Ultragenyx Pharmaceutical Inc. serves patients and healthcare providers across North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific region. Its role in the financial market reflects the specialized biopharmaceutical sector, where commercial products, regulatory expertise, manufacturing capabilities, and rare-disease research support access to targeted therapies and contribute to healthcare innovation.

CEO Dr. Emil D. Kakkis M.D., Ph.D. · 1,371 employees · United States · https://www.ultragenyx.com